CD44 and gastric cancer: (39) developed a hyaluronic acid (HA)-modified silica nanoparticle (HA-SiLN/QD) that reversed chemoresistance and remodeled tumor microenvironments by recognizing the overexpression of CD44 in gastric cancer cells and specifically targeting the delivery of quercetin and the gastric cancer chemotherapeutic agent adriamycin (DOX).